NCT02506517View on ClinicalTrials.gov

A Study of Afatinib in Patients With Advanced Cancer With Changes in the HER Gene

PHASE2CompletedINTERVENTIONAL

Enrollment

12

Participants

Timeline

Start Date

August 31, 2015

Primary Completion Date

May 4, 2023

Study Completion Date

May 4, 2023

Conditions

Solid Tumors

Interventions

DRUG

Afatinib

Trial Locations (1)

M5G 2M9

Princess Margaret Cancer Centre, Toronto

Sponsors

Collaborators (1)

Boehringer Ingelheim

All Listed Sponsors

collaborator

Boehringer Ingelheim

INDUSTRY

lead

University Health Network, Toronto

OTHER